Article Abstract

Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?

Authors: Alice Mogenet, Pascale Tomasini, Laurent Greillier, Fabrice Barlesi


Metastatic non-small cell lung cancer (NSCLC) remains the first cause of cancer-related death worldwide (1). Recent progress in the medical treatment of NSCLC have been focusing on molecular alterations. Anaplastic lymphoma kinase (ALK) rearrangements are found in about 3% to 5% of lung adenocarcinomas in western countries, more frequently non-smokers and younger patients than most NSCLC.